Cited by 174Thyroid Disorders and TreatmentsLipoproteins and Cardiovascular HealthHormonal and reproductive studies

Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study

Open access
IQBAL, A., JORDE, R., FIGENSCHAU, Y.·2006·Journal of Internal Medicine

Abstract

OBJECTIVE: To evaluate the relation between serum thyroid-stimulating hormone (TSH) and lipids. DESIGN: Cross-sectional epidemiological study, nested case-control study, and a placebo-controlled double-blind intervention study. METHODS: In the 5th Tromsø study serum TSH, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured. Subjects with subclinical hypothyroidism (SHT) and a matching control group were re-examined and apolipoprotein A1 (Apo A1) and apolipoprotein B (Apo B) were also measured. Subjects with SHT were included in an intervention study with thyroxine supplementation for 1 year. RESULTS: A total of 5143 subjects from the 5th Tromsø study were included. A significant and positive correlation between serum TSH levels and serum TC and LDL-C levels were found in both genders. However, in the females this did not reach statistical significance after adjusting for age and BMI. The serum LDL-C were significantly higher and the Apo A1 levels significantly lower in 84 SHT subjects compared with 145 controls, and in the SHT females the TC levels were also significantly elevated. In the intervention study (32 subjects given thyroxine and 32 subjects given placebo), we observed a significant reduction in the Apo B levels after thyroxine medication. In those that at the end of the study had serum TSH levels in the range 0.2-2.0 mIU L(-1), the serum TC and LDL-C levels were also significantly reduced. CONCLUSIONS: There is a positive association between serum TSH levels and TC and LDL-C levels. These lipid levels are reduced with thyroxine treatment in subjects with SHT.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2006.01652.x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two subsequent trials suggested that levothyroxine in subclinical hypothyroidism reduced low-density lipoprotein cholesterol by approximately 0.3 mmol/l (11.6 mg/dl).

    “Two subsequent trials suggested that the reduction of LDL-C was approximately 0.3 mmol/l (11.6 mg/dl) (16,41).”

    From Thyroid Hormones and Cardiovascular Function and Diseases (2018) · cites this paper as [41]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. e-mail: amjid.iqbal@unn.no). Ó 2006 Blackwell Publishing Ltd Journal of Internal Medicine 260: 53-61

Cited by

Sorted by citations

Authors
IQBAL, A., JORDE, R., & FIGENSCHAU, Y.
Affiliations
  • University Hospital of North Norway (NO)
  • UiT The Arctic University of Norway (NO)
Corresponding author
IQBAL, A.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2006-04-21
Volume
260
Issue
1
Pages
53-61
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2144225124
Cited by
174
References
30
Citations by year
2026: 5 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 7 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 10 · 2016: 16 · 2015: 9 · 2014: 16 · 2013: 12 · 2012: 19
FWCI
5.21
Type
journal article
Language
en
Open access
Locations
  • Journal of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Universitetet i Tromsø
  • EkstraStiftelsen Helse og Rehabilitering (Stiftelsen Dam)
  • Norges Forskningsråd
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
subclinical hypothyroidism, thyroid-stimulating hormone, serum lipids, thyroxine therapy, total cholesterol, LDL cholesterol, apolipoprotein A-I, apolipoprotein B, triglycerides, HDL cholesterol, sex differences
MeSH terms
Adult, Aged, Aged, 80 and over, Apolipoproteins B, Cholesterol, Epidemiologic Methods, Female, Humans, Hypothyroidism, Lipids, Cholesterol, LDL, Male, Middle Aged, Sex Factors, Thyrotropin, Thyroxine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review